Podcast by Dr. Cush
Listeners of Rheumnow Podcast that love the show mention: great, thank, dr cush.
The Rheumnow Podcast is an invaluable resource for anyone in the field of rheumatology or those with an interest in staying up to date with the latest research and news in this area. Hosted by Dr. Cush and his dedicated team, this podcast offers a concise and informative overview of important developments in the field on a weekly basis.
One of the best aspects of The Rheumnow Podcast is its ability to condense complex information into easily digestible segments. Dr. Cush's presentation style is engaging and clear, making it easy to follow even for those without an extensive background in rheumatology. The podcast covers a wide range of topics, including clinical pearls, conference reviews, and updates on new research findings. This comprehensive approach ensures that listeners are kept well-informed about the latest knowledge in the field.
Another positive aspect of this podcast is the dedication and effort put into its production. Dr. Cush and his team clearly invest a significant amount of time and energy into gathering the most relevant and important content for each episode. This commitment to providing high-quality educational material is evident in every episode, making it an invaluable resource for both practicing rheumatologists and those looking to expand their knowledge.
While there are many positive aspects to The Rheumnow Podcast, one potential drawback is its specialization in rheumatology. As mentioned by some reviewers, the content can be highly specialized and may not be as accessible or relevant for individuals outside of this field. However, given that this podcast is primarily targeted towards rheumatologists or those with a specific interest in rheumatology, it serves its purpose well.
In conclusion, The Rheumnow Podcast is an exceptional resource for staying updated with the latest knowledge in rheumatology. Dr. Cush's engaging presentation style coupled with his team's dedication to providing high-quality content make this podcast a must-listen for anyone involved in this field. Whether you're a practicing rheumatologist or simply interested in learning more about rheumatology, this podcast offers valuable insights and clinical pearls that can enhance patient care and keep you well-informed.
QD300: Flare or Beware (featuring Lindsay Tom, PA-C and Phong Nguyen, MD) QD301: CAR-T Cell Therapy for Lupus (featuring Philip Mease, MD and Cayla Alexander, DNP) QD302: Unweanable PMR (featuring Jack Cush, MD, and Leilani Law, APN) QD303: Weakness with Fibromyalgia (featuring Jack Cush, MD, and Leilani Law, APN)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salaries concerns.
Watch our kickoff webinar for this month's Mission: APP — Partners in Care campaign. Our panel of rheumatologists and experienced advanced practice providers share insights into hiring, onboarding, training, compensation, and more. Panelists: Philip Mease, MD Cayla Alexander, DNP, ARNP Kori Dewing, DNP, ANP-BC, ARNP Jack Cush, MD, Moderator
Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES 1. Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron's, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV 2. Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with JDM. https://t.co/i2HBycbWY9 3. Myelodysplastic & chr myelomonocytic leukemia pts rarely get lupus. Review of 19 w/ SLE & 5 w/ CLE; these were older (65 yrs), more male (15M/9F), w/ less renal [10%] & articular [36%] Dz w/ less dsDNA [32%]. Thought to be clonal inflammatory, & not autoinflammatory, process. https://t.co/EAvkJm6GQs 4. Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxnhttps://t.co/2qa7O2v6fm 5. No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj 6. Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww 7. Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1). 8. 25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/CYwVy7ls7y 9. ACR2025 Non-Renal Lupus Guidelines – from ACR Convergence 2025 10. 900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the 900,000 https://t.co/o7BaWjS4HB
Replay of RheumNow Live 2025 - Vasculitis Featuring: - Dr. Michael Wechsler: Management of EGPA in 2025 - Dr. Rennie Rhee: Imaging in Vasculitis - Dr. Richard Conway: Modern Treatment of PMR
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Check out: RNL 2026 – Feb 7 8 2026 DFW RheumNow.live
Replay of RheumNow Live 2025 - Spondyloarthritis Sponsored by AbbVie Featuring: Dr. Desiree van der Heidje - Advances in Treatment of Spondyloarthritis Dr. Jennifer Cather - Progress in Hidradenitis Supprativa Dr. Catherine Bakewell - Imaging Evaluation of Spondyloarthritis
Replay of RheumNow Live 2025 - Psoriatic Arthritis Sponsored by AbbVie Featuring: Dr. Alexis Ogdie - Can Aggressive Treatment of Psoriasis Prevent PsA? Dr. Artie Kavanaugh - Combination Biologic Therapies in PsA Dr. Kenneth Gordon - Head-to-head Studies in Psoriatic Disease – What have we learned?
Featuring: Dr. Jeffrey Curtis: AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect Dr. Una Makris: Key Considerations When Managing Older Adults with RA Dr. Bryant England: Who will manage multimorbidity in RA
A JAKi in GCA- Phase 3 Results Through 2 Years Sponsored by AbbVie Medical Affairs + Health Impact
A focused discussion on updates in spondyloarthritis, including emerging data, treatment strategies, and real-world care considerations. Hear expert perspectives and practical takeaways shaping SpA management today.
A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.
A focused conversation on the latest in psoriatic arthritis care — from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now.
A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now.
Stay plugged into the conversations, discoveries, and breakthroughs moving rheumatology forward. Real updates. Real context. For clinicians who never stop learning.
Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our Videos and podcasts.
NEPTUNUS: Ianalumab in Sjogren's Pulmonary hypertension in Sarcoidosis
Restoring B Cell Compartments with CAR T: Molecular Data is Here CAR-T: The Future
Revised Classification Criteria in axSpA https://www.youtube.com/watch?v=voFJrQo1ANU NSAID Addition Helps the Spine but not the Hips https://www.youtube.com/watch?v=wTKMC1MTwpE Biomarker Discovery in axSpA https://www.youtube.com/watch?v=X8Sc_3oBSVA Sexual Function in axSpA https://www.youtube.com/watch?v=r4_Nsh7e_oo Coping Strategies in axSpA https://www.youtube.com/watch?v=z9KdNuOu4nI "ROC-SpA Study" https://www.youtube.com/watch?v=kIEN39XRsSM Why do patients stay in clinical trials? https://www.youtube.com/watch?v=pVIBoN0jO2o What to do after first TNR failure in axSpA? https://www.youtube.com/watch?v=PVSyq_Y5-PE
ILD in Patients with Connective Tissue Disease Fiber and Methotrexate RA ILD Prediction: simple as a dipstick? "Leftover Pain in Inflammatory Arthritis"
From Pain to Wellness in PsA Secukinumab vs Ustekinumab in PsA Izokibep: still enthused about enthesitis? Using Digital Apps to Modify Pain in axSpA
"ROC-SpA Study" Secukinumab vs Ustekinumab in PsA RA ILD Prediction: simple as a dipstick? Sjogren's Disease: PROs as a Filter for Precision Medicine Why do patients stay in clinical trials? Using Digital Apps to Modify Pain in axSpA IgG4: Rare but Treatable!
From Pain to Wellness in PsA IL-2 Therapy in SLE? Maybe Sexual Function in axSpA "Fact or Fiction: Trinetics Research at ACR" CD1/BCMA Dual Targeting: One too many targets in SLE Hydroxychloroquine Blood Levels The Great Debate: AI in Rheumatology Coping Strategies in axSpA "What to do After First TNR Failure in axSpA"
Join panelists Drs. Brian Jaros, Akhil Sood and Michael Putman as they recap highlights from Day 4, the final day of the 2025 ACR Convergence meeting in Chicago.
Join RheumNow Faculty Drs. Shelia Reyes, Mike Putman, Bella Mehta, and Jack Cush as they discuss highlights and key takeaways from the Day 3 Recap, at the 2025 ACR Convergence meeting in Chicago.
Join RheumNow Faculty Drs. Shelia Reyes, Mike Putman, Bella Mehta, and Jack Cush as they discuss highlights and key takeaways from the Day 3 Recap, at the 2025 ACR Convergence meeting in Chicago.
Screen RA ILD Properly Rheumatoid Arthritis Highlights Predicting Rheumatoid Arthritis GDF-15: How Depression is Related to Lung Disease in RA
"Leftover Pain in Inflammatory Arthritis" Another Specialized Biomarker in PsA Secrets and Pearls in Rheumatology What's the latest in PsA?
GDF-15: How Depression is Related to Lung Disease in RA What Can we do About Chronic Pain? What's the latest in PsA? What to do after first TNR failure in axSpA?
Secrets and Pearls in Rheumatology Addressing Lupus Nephritis Timely Fake Rheum Diagnostic Dilemmas Rheumatoid Arthritis Highlights Restoring B Cell Compartments with CAR T: Molecular Data is Here Predicting Rheumatoid Arthritis h What Causes Infection in Vasculitis? Is it All About the Weight Loss? Izokibep: still enthused about enthesitis? T Cell Engagers: Are we engaged? Fiber and Methotrexate
Spondyloarthritis: The CLASSIC Study "Leftover Pain in Inflammatory Arthritis" NeuroImmune Modulation in RA: Results of the RESET RA Trial Change it or Keep it? TNF in Axial SpA Perspectives on CAR T Therapy Addressing Lupus Nephritis Early Addressing Lupus Nephritis Aggressively CAR-T: The Future Biomarker Discovery in axSpA Another Specialized Biomarker in PsA Revised Classification Criteria in axSpA
Catching AxSpA Early: Closing the Diagnostic Gap Early Peripheral SpA: Is it okay to stop treatment sometimes? Difficult to Manage axSpA Tofacitinib in AxSpA in Developing Countries Late-Breaking Trials in axSpA and PsA Durability and Safety of Bimekizumab Biologics Improve Sexual Function in axSpA Multidimensional Pain inventory in Axial SpA Spondyloarthritis: The CLASSIC Study Change it or Keep it? TNF in Axial SpA "Leftover Pain in Inflammatory Arthritis"
B Cell Depletion: Check the Lymph Node "Next Generation T-Cell Engager: The Future" Off the Shelf: CAR-T Combining CAR-T with CAR-Treg All in One CAR-T Therapy: Where is it Heading? Safety of CAR-T New Paradigms in RA Treatment Perspectives on CAR T Therapy
Wired for Success: Vagal Nerve Therapy in RA RA: Does upfront TNFi save heartache? New Paradigms in RA Treatment
SLGT-2 and GLP-1 in RA: More than Weight Loss ACR2025 Day 1 RECAP
Cellular Biomarkers of Rheumatoid Arthritis Day 2 Recap: ACR Convergence 2025 Highlights
STOP RA Cellular & Serologic Predictors Rheumatoid Arthritis: Inject the Steroids Is Low Disease Activity Low Enough?
Catching PsA before it Starts Day 2 Recap: ACR Convergence 2025 Highlights
PsA and Brain Fog GLP-1 Receptor Agonists in PsA: Mortality and MACE PsA Predictors When the Back Hurts: uncovering BASDAI drivers in PsA The Upper Hand in PsA? Not the Dominant One
Diagnostic Delays in PsA: A Radiographic Perspective Late-Breaking Trials in axSpA and PsA New Approaches to Therapy in PsA
Psoriatic Arthritis Imaging Specialized Biomarkers in PsA PsA: Impact of Sex GLP-1 and SGLT-2: Treatments Too Good to Ignore?
Safety of NSAIDs in Inflammatory Bowel Disease Screen RA ILD Properly Biologics Improve Sexual Function in axSpA Catching PsA before it Starts Multidimensional Pain inventory in Axial SpA RA: Does upfront TNFi save heartache? Novel Insights into Sjogren's Disease New Paradigms in RA Treatment Biomarkers in Still's and Macrophage Activation Syndrome "The Power of Gamma Delta T Cell for Autoimmunity" The Heartbreak of Sarcoidosis
NSAID Addition Helps the Spine but not the Hips Durability and Safety of Bimekizumab Progressive BiTE in SLE 2 Hydroxychloroquine Reduces Autoantibody Levels When the Back Hurts: uncovering BASDAI drivers in PsA The Upper Hand in PsA? Not the Dominant One Airway Disease in GPA Wired for Success: Vagal Nerve Therapy in RA GLP-1 in Knee Osteoarthritis Disparities in Physical Function in SLE
Putting Steroid Tapering into Practice in SLE Tocilizumab Beats Methotrexate in GCA GLP-1 Receptor Agonists in PsA: Mortality and MACE Safety of CAR-T ILD in Patients with Connective Tissue Disease SLGT-2 and GLP-1 in RA: More than Weight Loss PsA Predictors Ianalumab: Breakthrough Therapy in Sjogren's
Off the Shelf: CAR-T Combining CAR-T with CAR-Treg All in One Tapering in SELECT GCA: Steroids are the Problem Diagnostic Delays in PsA: A Radiographic Perspective Late-Breaking Trials in axSpA and PsA New Approaches to Therapy in PsA PRED-SAFE: Chronic Prednisone Use PsA and Brain Fog CAR-T Therapy: Where is it Heading?
Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap on Monday, October 27th, at the 2025 ACR Convergence meeting in Chicago.
A Nose for Vasculitis: ENT Manifestations in ANCA-Associated Disease Tofacitinib in AxSpA in Developing Countries Specialized Biomarkers in PsA B Cell Depletion: Check the Lymph Node GLP-1 and SGLT-2: Treatments Too Good to Ignore? Nerandomilast for ILD PsA: Impact of Sex Cellular Biomarkers of Rheumatoid Arthritis Using AI and LLMs in Qualitative Data Belimumab Before or After Immunosuppressant Do Patients with Rheumatic Diseases 'Weather' the Storm? AI in Fellow Recruitment: A New Dawn in Medical Education?
AI Scribes Found their Favorite Doctors Hospitalization in Stills: Is it "Still" an Infection? Upadacitinib is a Double Edged Vascular Sword in GCA Rheumatoid Arthritis: Inject the Steroids Catching AxSpA Early: Closing the Diagnostic Gap Is Low Disease Activity Low Enough? Early Peripheral SpA: Is it okay to stop treatment sometimes? Difficult to Manage axSpA
© 2020-2025 Ivy Podcast Discovery LLC
